Immunotherapy in Urothelial Carcinoma: Fade or Future Standard?

Overview

Journal Transl Androl Urol

Date 2016 Oct 28

PMID 27785423

Citations 1

Authors

Johannes Breyer

Maximilian Burger

Wolfgang Otto

Affiliations

Soon will be listed here.

Abstract

Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.

Citing Articles

Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.

Wu S, Xu R, Li X, Zhao X, Qian B Oncotarget. 2018; 9(38):25294-25303.

PMID: 29861872 PMC: 5982745. DOI: 10.18632/oncotarget.25334.

References

Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P . Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis. 2000; 79(4):243-50. DOI: 10.1054/tuld.1999.0206. View

Otto W, Denzinger S, Wieland W, Hartmann A . First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. World J Urol. 2012; 30(6):875-7. DOI: 10.1007/s00345-012-0974-2. View

Bohle A, Jocham D, Bock P . Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2002; 169(1):90-5. DOI: 10.1016/S0022-5347(05)64043-8. View

Beck K, Blansfield J, Tran K, Feldman A, Hughes M, Royal R . Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24(15):2283-9. PMC: 2140223. DOI: 10.1200/JCO.2005.04.5716. View

Golka K, Rettenmeier A, Goebell P . [The causes of urinary bladder cancer and possibilities of prevention]. Urologe A. 2006; 45(3):361-7. DOI: 10.1007/s00120-006-1018-6. View

Fuge O, Vasdev N, Allchorne P, Sa Green J . Immunotherapy for bladder cancer. Res Rep Urol. 2015; 7:65-79. PMC: 4427258. DOI: 10.2147/RRU.S63447. View

Otto W, Denzinger S, Fritsche H, Burger M, Wieland W, Hofstadter F . The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2010; 107(3):404-8. DOI: 10.1111/j.1464-410X.2010.09515.x. View

Rentsch C, Birkhauser F, Biot C, Gsponer J, Bisiaux A, Wetterauer C . Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014; 66(4):677-88. DOI: 10.1016/j.eururo.2014.02.061. View

Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Kufer R . Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2013; 40(1):121-7. DOI: 10.1016/j.ejso.2013.08.023. View

10.

Topalian S, Drake C, Pardoll D . Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2):207-12. PMC: 3319479. DOI: 10.1016/j.coi.2011.12.009. View

11.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

12.

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

13.

Biot C, Rentsch C, Gsponer J, Birkhauser F, Jusforgues-Saklani H, Lemaitre F . Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012; 4(137):137ra72. DOI: 10.1126/scitranslmed.3003586. View

14.

Otto W, May M, Fritsche H, Dragun D, Aziz A, Gierth M . Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med. 2012; 9(6):481-9. DOI: 10.1016/j.genm.2012.11.001. View

15.

Carthon B, Wolchok J, Yuan J, Kamat A, Ng Tang D, Sun J . Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010; 16(10):2861-71. PMC: 2919850. DOI: 10.1158/1078-0432.CCR-10-0569. View

16.

Yang J, Hughes M, Kammula U, Royal R, Sherry R, Topalian S . Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30(8):825-30. PMC: 2134980. DOI: 10.1097/CJI.0b013e318156e47e. View

17.

Shelley M, Wilt T, COURT J, Coles B, Kynaston H, Mason M . Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004; 93(4):485-90. DOI: 10.1111/j.1464-410x.2003.04655.x. View

18.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

19.

van der Meijden A, Sylvester R, Oosterlinck W, Hoeltl W, Bono A . Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003; 44(4):429-34. DOI: 10.1016/s0302-2838(03)00357-9. View

20.

Shelley M, Kynaston H, COURT J, Wilt T, Coles B, Burgon K . A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001; 88(3):209-16. DOI: 10.1046/j.1464-410x.2001.02306.x. View